Latest Hotspot

Tourmaline Bio Starts Phase 2 Trials of TOUR006 for Cardiovascular Disease

24 May 2024
3 min read

Tourmaline Bio, Inc., a biotechnology firm in the advanced stages of clinical development focusing on breakthrough treatments for severe immune and inflammatory disorders, revealed that it has administered the first dose to a patient in its Phase 2 TRANQUILITY trial. This event signifies the official start of their clinical program for TOUR006, an extended-duration, fully human anti-IL-6 monoclonal antibody, aimed at treating atherosclerotic cardiovascular disease and other related cardiovascular conditions.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

TRANQUILITY represents a randomized, double-blind, placebo-controlled study targeting patients with an inflammatory risk profile, indicated by elevated baseline high-sensitivity C-reactive protein, and chronic kidney disease.

"There's an urgent need for novel treatments for the vast number of patients who continue to face a high risk of heart attack, stroke, acute limb ischemia, and mortality, despite conventional risk factor adjustments," stated Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline and former Medical Director of the Preventive Cardiovascular Program at the University of Pennsylvania.

"Evidence converging from IL-6 human genetic research, epidemiological investigations, and mechanistic studies, along with data from clinical trials on IL-6 inhibition, strongly supports the therapeutic potential of IL-6 inhibition for patients with ASCVD as well as other cardiovascular conditions, including heart failure," deGoma added.

The TRANQUILITY study design incorporates insights from six previous Phase 1 and Phase 2 studies of TOUR006. If successful, outcomes from the Phase 2 TRANQUILITY study are expected to prepare Tourmaline for Phase 3 trials in 2025 for ASCVD and other cardiovascular conditions.

"TOUR006 presents a unique 'pipelines in a product' opportunity, addressing both severe cardiovascular diseases driven by IL-6 inflammation and serious autoimmune disorders, such as thyroid eye disease," elaborated Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. 

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of May 23, 2024, there are 61 investigational drugs for the IL-6 targets, including 315 indications, 165 R&D institutions involved, with related clinical trials reaching 1811, and as many as 73156 patents.

TOUR006 is a long-acting, fully human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. TOUR006 has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing TOUR006 in thyroid eye disease and atherosclerotic cardiovascular disease as its first two indications, with additional diseases under consideration.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

CASI Pharmaceuticals Receives FDA Approval for New ITP Drug CID-103
Latest Hotspot
3 min read
CASI Pharmaceuticals Receives FDA Approval for New ITP Drug CID-103
24 May 2024
CASI Pharmaceuticals Gets FDA Approval For Investigational New Drug CID-103 In Treating Immune Thrombocytopenia (ITP).
Read →
Ractigen Therapeutics Gets NMPA Approval for Phase 1 Trials of RAG-17 in Chinese ALS Patients
Latest Hotspot
3 min read
Ractigen Therapeutics Gets NMPA Approval for Phase 1 Trials of RAG-17 in Chinese ALS Patients
24 May 2024
Ractigen Therapeutics Gains NMPA Clearance to Begin Phase 1 Trials of RAG-17 in Chinese SOD1-ALS Patients.
Read →
Weekly Insulin Efsitora Alfa Reduces A1C and Matches Daily Insulin Safety
Latest Hotspot
3 min read
Weekly Insulin Efsitora Alfa Reduces A1C and Matches Daily Insulin Safety
24 May 2024
With Weekly Dosing, Insulin Efsitora Alfa Achieves A1C Reduction and Matches Safety of Daily Insulin.
Read →
Iterion Begins Tegavivint Phase 1b/2a Trial for Advanced HCC Patients After Systemic Treatment Failure
Pharma Pioneer
3 min read
Iterion Begins Tegavivint Phase 1b/2a Trial for Advanced HCC Patients After Systemic Treatment Failure
24 May 2024
Biopharmaceutical firm Iterion Therapeutics has initiated a Phase 1b/2a clinical trial for its lead drug candidate, tegavivint, which is designed to inhibit Transducin beta-like protein 1 (TBL1).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.